Medtronic, (headquartered in Dublin, Ireland), the global leader in medical technology, announced U.S. Food and Dru...
Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world's largest Italian biopharmaceutical comp...
Sinovac Biotech, a leading provider of biopharmaceutical products in China, has received a drug registration approval fr...
In conjunction with the IAS Conference on HIV Science, Germany's Frontier Biotechnologies has announced positive top-lin...
Eisai's Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofic...
The European Commission has granted marketing authorization for Jardiance®(empagliflozin) as a treatment for adults ...
Japanese scientists are scanning the possibility of using an anti-malarial drug called mefloquine....
eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and ...
Vectura Group has signed an agreement with Australia-based Incannex Healthcare to provide pre-clinical development servi...
Rancho Santa Fe Bio, Inc. (RSF Bio), a San Diego, California-based clinical-stage cardiovascular platform company, annou...
Merck has signed a collaboration agreement with Janssen Pharmaceuticals NV around the commercialization of INVOKANA...
Peptron, Inc., a South Korea-based biotech company, and Qilu Pharmaceutical, a China-based pharmaceutical company f...
The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments ...
SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced that cenobamate received marketi...
Sydney-based Kazia Therapeutics Limited, an oncology-focused drug development company announced that it has entered into...
Astellas Pharma Inc. announced on March 31, 2021, that XOSPATA® (generic name: gilteritinib) is now available for pr...
Eisai Co., Ltd. announced on March 30, 2021 that the European Medicines Agency (EMA) has confirmed it has acce...
EirGenix, Inc. announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimi...
